MI-773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1

Oncol Lett. 2021 Dec;22(6):838. doi: 10.3892/ol.2021.13099. Epub 2021 Oct 18.

Abstract

Neuroblastoma (NB) is a common pediatric malignancy associated with poor outcomes. Recent studies have shown that murine double minute2 homolog (MDM2) protein inhibitors are promising anticancer agents. MI-773 is a novel and specific antagonist of MDM2, however, the molecular mechanism of its anti-NB activity remains unclear. NB cell viability was measured by Cell Counting Kit-8 assay following MI-773 treatment. Cell cycle progression was analyzed using PI staining and apoptosis was assessed using Annexin V/PI staining. The molecular mechanisms by which MI-773 exerted its effects were investigated using a microarray. The results showed that disturbance of the MDM2/p53 axis by MI-773 resulted in potent suppression of proliferation, induction of apoptosis and cell cycle arrest in NB cells. In addition, microarray analysis showed that MI-773 led to significant downregulation of genes involved in the G2/M phase checkpoint and upregulation of hallmark gene associated with the p53 pathway. Meanwhile, knockdown of insulinoma-associated 1 decreased proliferation and increased apoptosis of NB cells. In conclusion, the present study demonstrated that MI-773 exhibited high selectivity and blockade affinity for the interaction between MDM2 and TP53 and may serve as a novel strategy for the treatment of NB.

Keywords: MI-773; insulinoma-associated 1; murine double minute2 homolog; neuroblastoma; p53.

Grants and funding

The present study was supported by grants from Natural Science Fund for Colleges and Universities of Jiangsu Province (grant no. 18KJB320022); the National Natural Science Foundation (grant nos. 82072767, 81770145, 81702339, 81701596, 817072737, 81802499, 81872845, 81902534, 81971867 and 81902534); Natural Science Foundation of Jiangsu Province (grant nos. BK20180207, BK20180206, SBK2019021442, BK20191175 and BK20190185); Jiangsu Provincial Medical Youth Talent (grant nos. QNRC2016762, QNRC2016756, QNRC2016758 and QNRC2016768); Gusu Health Talents Program of Soochow City (grant no. 2020-104); Department of Pediatrics Clinical Center of Suzhou (grant no. Szzx201504); Applied Foundational Research of Medical and Health Care of Suzhou City (grant nos. SYS2019080, SYS2019082, SYS2018075, SYS2018074, SYS2019077 and SS201809); Accented Term of Jiangsu Provincial Health Commission (grant no. K2019005); Suzhou Special Foundation of Clinical Key Diseases Diagnosis and Therapy (grant no. LCZX201907).